Advances in Host-Directed Therapies Against Tuberculosis / Karakousis, Petros C. ; Hafner, Richard ; Gennaro, Maria Laura  

Público ISBD Ningún comentario para este registro. Título : Advances in Host-Directed Therapies Against Tuberculosis Tipo de documento: documento electrónico Autores: Karakousis, Petros C., ; Hafner, Richard, ; Gennaro, Maria Laura, Mención de edición: 1 ed. Editorial: [s.l.] : Springer Fecha de publicación: 2021 Número de páginas: XIII, 332 p. 20 ilustraciones ISBN/ISSN/DL: 978-3-030-56905-1 Nota general: Libro disponible en la plataforma SpringerLink. Descarga y lectura en formatos PDF, HTML y ePub. Descarga completa o por capítulos. Idioma : Inglés (eng) Palabras clave: Inmunología  Enfermedades  Terapéutica Clasificación: 571.96 Resumen: Este libro analiza vías reguladoras de células inmunitarias específicas, tipos de células inmunitarias u otros mecanismos implicados en las respuestas del huésped a la tuberculosis que pueden ser potencialmente objetivo de la terapia dirigida al huésped (HDT). Las vías/mecanismos investigados son protectores (por lo que requieren fármacos potenciadores de vías/factores) o desadaptativos (por lo que requieren fármacos inhibidores de vías/factores). También se aclarará el descubrimiento y desarrollo (preclínico y clínico) de agentes candidatos para la HDT, así como enfoques para la HDT de otras enfermedades. El beneficio para el lector se derivará de aprender sobre la biología de múltiples vías del huésped involucradas en la salud y la enfermedad, cómo estas vías se interrumpen o desregulan durante la tuberculosis y qué objetivos farmacológicos existen en estas vías. Este libro proporciona al lector una hoja de ruta de las direcciones actuales y futuras de la HDT contra la tuberculosis. Dado que las vías/factores del huésped involucrados en las respuestas protectoras o desadaptativas a la tuberculosis no son específicos de la enfermedad, la información aprendida del contexto de la tuberculosis probablemente será relevante para otras enfermedades infecciosas y no infecciosas. Nota de contenido: Section 1: Introduction -- Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis -- Section 2: Targeting immunometabolism -- Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism -- Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells -- Chapter 4: HIF-1α as a potential therapeutic target for tuberculosis treatment -- Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis -- Section 3: Enhancing anti-mycobacterial mechanisms -- Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis -- Chapter 7: Metformin: a leading HDT candidate for TB -- Chapter 8: Statins as host-directed therapy for tuberculosis -- Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms -- Section 4: Targeting immune cells -- Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis -- Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma -- Chapter 12: Targeting suppressor T cells -- Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis -- Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis -- Chapter 15: Mucosal-associated invariant and Vγ9Vδ2 T cells -- Chapter 16: Airway epithelial cells.-Section 5: Preclinical models for assessing HDTs -- Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies -- Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis -- Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis -- Section 6: Clinical trials of HDTs and special considerations for study endpoints -- Chapter 20:Clinical trials of TB-HDT candidates -- Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis -- Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis. Tipo de medio : Computadora Summary : This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/factor enhancing drugs – or maladaptive – thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases. Enlace de acceso : https://link-springer-com.biblioproxy.umanizales.edu.co/referencework/10.1007/97 [...] Advances in Host-Directed Therapies Against Tuberculosis [documento electrónico] / Karakousis, Petros C., ; Hafner, Richard, ; Gennaro, Maria Laura,  . -  1 ed.  . - [s.l.] : Springer, 2021 . - XIII, 332 p. 20 ilustraciones. ISBN : 978-3-030-56905-1 Libro disponible en la plataforma SpringerLink. Descarga y lectura en formatos PDF, HTML y ePub. Descarga completa o por capítulos. Idioma : Inglés (eng) Palabras clave: Inmunología  Enfermedades  Terapéutica Clasificación: 571.96 Resumen: Este libro analiza vías reguladoras de células inmunitarias específicas, tipos de células inmunitarias u otros mecanismos implicados en las respuestas del huésped a la tuberculosis que pueden ser potencialmente objetivo de la terapia dirigida al huésped (HDT). Las vías/mecanismos investigados son protectores (por lo que requieren fármacos potenciadores de vías/factores) o desadaptativos (por lo que requieren fármacos inhibidores de vías/factores). También se aclarará el descubrimiento y desarrollo (preclínico y clínico) de agentes candidatos para la HDT, así como enfoques para la HDT de otras enfermedades. El beneficio para el lector se derivará de aprender sobre la biología de múltiples vías del huésped involucradas en la salud y la enfermedad, cómo estas vías se interrumpen o desregulan durante la tuberculosis y qué objetivos farmacológicos existen en estas vías. Este libro proporciona al lector una hoja de ruta de las direcciones actuales y futuras de la HDT contra la tuberculosis. Dado que las vías/factores del huésped involucrados en las respuestas protectoras o desadaptativas a la tuberculosis no son específicos de la enfermedad, la información aprendida del contexto de la tuberculosis probablemente será relevante para otras enfermedades infecciosas y no infecciosas. Nota de contenido: Section 1: Introduction -- Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis -- Section 2: Targeting immunometabolism -- Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism -- Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells -- Chapter 4: HIF-1α as a potential therapeutic target for tuberculosis treatment -- Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis -- Section 3: Enhancing anti-mycobacterial mechanisms -- Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis -- Chapter 7: Metformin: a leading HDT candidate for TB -- Chapter 8: Statins as host-directed therapy for tuberculosis -- Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms -- Section 4: Targeting immune cells -- Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis -- Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma -- Chapter 12: Targeting suppressor T cells -- Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis -- Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis -- Chapter 15: Mucosal-associated invariant and Vγ9Vδ2 T cells -- Chapter 16: Airway epithelial cells.-Section 5: Preclinical models for assessing HDTs -- Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies -- Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis -- Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis -- Section 6: Clinical trials of HDTs and special considerations for study endpoints -- Chapter 20:Clinical trials of TB-HDT candidates -- Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis -- Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis. Tipo de medio : Computadora Summary : This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/factor enhancing drugs – or maladaptive – thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases. Enlace de acceso : https://link-springer-com.biblioproxy.umanizales.edu.co/referencework/10.1007/97 [...]

---

1 (1 - 1 / 1) Ver por página : 25 50 100 200